News for Healthier Living

Andelyn Biosciences Applies the AAV Curator(r) Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after Diagnosis

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has successfully manufactured a novel viral vector gene therapy with its AAV Curator(r) Platform to treat a baby with the ultra-rare disease Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS).

May 12, 2025


May 15 2025

May 14 2025

May 13 2025

May 12 2025

May 11 2025

May 10 2025

May 9 2025

May 8 2025

May 7 2025

May 6 2025

May 5 2025

May 2 2025

May 1 2025